Summary

The 7 major attention deficit hyperactivity disorder markets reached a value of US$ 9.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 13.6 Billion by 2034, exhibiting a growth rate (CAGR) of 3.23% during 2024-2034.

The attention deficit hyperactivity disorder market has been comprehensively analyzed in IMARC's new report titled "Attention Deficit Hyperactivity Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Attention deficit hyperactivity disorder (ADHD) refers to a neurodevelopmental condition that can affect people of all ages. The indications of the ailment can be grouped into two main categories: inattention and hyperactivity/impulsivity. Inattention symptoms may include difficulty with organization and time management, forgetfulness, distractibility, problems with sustained attention and task completion, etc. Hyperactivity/impulsivity symptoms are fidgeting, restlessness, difficulty sitting still, impulsivity, interrupting or speaking out of turn, etc. Individuals with ADHD may also struggle with social skills, emotion regulation, and academic or occupational performance. Diagnosing the ailment typically involves a comprehensive evaluation by a qualified healthcare professional. The assessment includes a detailed medical history, including information about developmental milestones, family history, and past as well as present symptoms. Medical professionals also use rating scales or checklists to help identify signs and evaluate their severity. In some cases, they may perform additional testing, such as neurological or psychological testing, to rule out other conditions that resemble ADHD indications.

The growing cases of developmental variations in some regions of the brain that are involved in attention and impulse control, such as the prefrontal cortex, basal ganglia, cerebellum, etc., are primarily driving the attention deficit hyperactivity disorder market. Furthermore, the widespread adoption of various stimulant medications, including Ritalin and Adderall, which work by increasing the levels of dopamine and norepinephrine in the brain to improve attention as well as reduce hyperactivity and impulsivity, is creating a positive outlook for the market. Apart from this, the escalating utilization of neurofeedback for helping individuals with ADHD regulate their brain activity and improve symptoms associated with the ailment is acting as another significant growth-inducing factor. Additionally, the rising demand for cognitive-behavioral therapy (CBT) that focuses on changing thought patterns and behaviors in individuals who struggle with negative self-talk, anxiety, and depression is also augmenting the market growth. Moreover, the emerging popularity of non-stimulant medications on account of their several associated benefits, including lower risk of abuse or dependence, fewer side effects, and better effectiveness in treating both ADHD symptoms as well as co-occurring conditions, is expected to drive the attention deficit hyperactivity disorder market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the attention deficit hyperactivity disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for attention deficit hyperactivity disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the attention deficit hyperactivity disorder market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the attention deficit hyperactivity disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the attention deficit hyperactivity disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current attention deficit hyperactivity disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the attention deficit hyperactivity disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the attention deficit hyperactivity disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the attention deficit hyperactivity disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of attention deficit hyperactivity disorder across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of attention deficit hyperactivity disorder by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of attention deficit hyperactivity disorder by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with attention deficit hyperactivity disorder across the seven major markets?
What is the size of the attention deficit hyperactivity disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of attention deficit hyperactivity disorder?
What will be the growth rate of patients across the seven major markets?

Attention Deficit Hyperactivity Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for attention deficit hyperactivity disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the attention deficit hyperactivity disorder market?
What are the key regulatory events related to the attention deficit hyperactivity disorder market?
What is the structure of clinical trial landscape by status related to the attention deficit hyperactivity disorder market?
What is the structure of clinical trial landscape by phase related to the attention deficit hyperactivity disorder market?
What is the structure of clinical trial landscape by route of administration related to the attention deficit hyperactivity disorder market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Source
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Attention Deficit Hyperactivity Disorder - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Attention Deficit Hyperactivity Disorder - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Attention Deficit Hyperactivity Disorder - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Attention Deficit Hyperactivity Disorder - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Attention Deficit Hyperactivity Disorder - Unmet Needs

10 Attention Deficit Hyperactivity Disorder - Key Endpoints of Treatment

11 Attention Deficit Hyperactivity Disorder - Marketed Products
11.1 List of Attention Deficit Hyperactivity Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Azstarys (Serdexmethylphenidate/dexmethylphenidate) - Zevra Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Focalin (Dexmethylphenidate) - Celgene/Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Vyvanse (Lisdexamfetamine) - Shionogi/Takeda
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Quillivant XR (Methylphenidate extended-release oral suspension) - Tris Pharma
11.1.4.1 Drug Overview
11.1.4.1 Mechanism of Action
11.1.4.2 Regulatory Status
11.1.4.3 Clinical Trial Results
11.1.4.4 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Attention Deficit Hyperactivity Disorder - Pipeline Drugs
12.1 List of Attention Deficit Hyperactivity Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 Centanafadine - Otsuka Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 PDC1421 - BioLite, Inc.
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CTX 1301 - Cingulate Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Mazindol - NLS Pharmaceutics Ltd
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 CX717 - RespireRx
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Attention Deficit Hyperactivity Disorder - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Attention Deficit Hyperactivity Disorder – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Attention Deficit Hyperactivity Disorder - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Attention Deficit Hyperactivity Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Attention Deficit Hyperactivity Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Attention Deficit Hyperactivity Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Attention Deficit Hyperactivity Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Attention Deficit Hyperactivity Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Attention Deficit Hyperactivity Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Attention Deficit Hyperactivity Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Attention Deficit Hyperactivity Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview

16 Attention Deficit Hyperactivity Disorder - Recent Events and Inputs From Key Opinion Leaders

17 Attention Deficit Hyperactivity Disorder Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Attention Deficit Hyperactivity Disorder Market – Strategic Recommendations

19 Appendix